These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 16437251

  • 1. Optimal antidiarrhea treatment for antitumor agent irinotecan hydrochloride (CPT-11)-induced delayed diarrhea.
    Takasuna K, Hagiwara T, Watanabe K, Onose S, Yoshida S, Kumazawa E, Nagai E, Kamataki T.
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):494-503. PubMed ID: 16437251
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T.
    Cancer Chemother Pharmacol; 1998 Oct; 42(4):280-6. PubMed ID: 9744772
    [Abstract] [Full Text] [Related]

  • 4. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
    Takasuna K, Kasai Y, Kitano Y, Mori K, Kobayashi R, Hagiwara T, Kakihata K, Hirohashi M, Nomura M, Nagai E.
    Jpn J Cancer Res; 1995 Oct; 86(10):978-84. PubMed ID: 7493918
    [Abstract] [Full Text] [Related]

  • 5. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T.
    Cancer Res; 1996 Aug 15; 56(16):3752-7. PubMed ID: 8706020
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor.
    Yang XX, Hu ZP, Xu AL, Duan W, Zhu YZ, Huang M, Sheu FS, Zhang Q, Bian JS, Chan E, Li X, Wang JC, Zhou SF.
    J Pharmacol Exp Ther; 2006 Oct 15; 319(1):82-104. PubMed ID: 16815871
    [Abstract] [Full Text] [Related]

  • 14. Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats.
    Fittkau M, Voigt W, Holzhausen HJ, Schmoll HJ.
    J Cancer Res Clin Oncol; 2004 Jul 15; 130(7):388-94. PubMed ID: 15160289
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo.
    Cheng KW, Tseng CH, Tzeng CC, Leu YL, Cheng TC, Wang JY, Chang JM, Lu YC, Cheng CM, Chen IJ, Cheng YA, Chen YL, Cheng TL.
    Pharmacol Res; 2019 Jan 15; 139():41-49. PubMed ID: 30391354
    [Abstract] [Full Text] [Related]

  • 17. [Study on the mechanisms of diarrhea induced by a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats].
    Takasuna K, Kasai Y, Kitano Y, Mori K, Kakihata K, Hirohashi M, Nomura M.
    Nihon Yakurigaku Zasshi; 1995 Jun 15; 105(6):447-60. PubMed ID: 7557733
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
    Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, Bonnay M, Herait P, Cote C, Mahjoubi M, Mignard D, Cvitkovic E.
    J Clin Oncol; 1998 Aug 15; 16(8):2745-51. PubMed ID: 9704727
    [Abstract] [Full Text] [Related]

  • 20. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer.
    Mori K, Kondo T, Kamiyama Y, Kano Y, Tominaga K.
    Cancer Chemother Pharmacol; 2003 May 15; 51(5):403-6. PubMed ID: 12687289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.